Abstracts tagged "Animal models"

Abstract Number: 2231 • 2017 ACR/ARHP Annual Meeting
MCC22, a Novel Compound That Targets Both CCR5 and Mu Opioid Receptors, Is Highly Effective in Treating Inflammatory Arthritis Pain
Raini Dutta¹, Mary Lunzer², Jennifer L. Auger³, Eyup Akgün², Philip Porthoghese² and Bryce A. Binstadt³, ¹Pediatrics, University of Minnesota, Minneapolis, MN, ²Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, ³Center for Immunology and Department of Pediatrics, University of Minnesota, Minneapolis, MN
Background/Purpose: The pain that accompanies rheumatoid arthritis and other chronic inflammatory conditions is difficult to manage. Although opioids provide potent analgesia, chronic opioid use is…
Abstract Number: 407 • 2017 ACR/ARHP Annual Meeting
Selective Inhibition of Tfh Cells By a Small Molecule Inhibitor Abrogates Progression of Experimental Inflammatory Arthritis
Frank Migliore¹, Sedrick Bradley¹, Linh Hellmers¹, Quretul Quresh², Jerald M. Zakem³, William E. Davis³, Tamika Webb-Detiege¹, Zongbing You⁴, Robert Quinet² and Xin Zhang⁵, ¹Ochsner Clinic Foundation, New Orleans, LA, ²Rheumatology, Ochsner Medical Center, New Orleans, LA, ³University of Queensland School of Medicine, Brisbane, Australia, ⁴Tulane University Health Science Center, New Orleans, LA, ⁵Laboratory of Cellular Immunology, Institution of Translational Research, Ochsner Medical Center, New Orleans, LA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune disease characterized by progressive infiltration of the joints by T cells and other leukocytes, production of…
Abstract Number: 1335 • 2017 ACR/ARHP Annual Meeting
p62/SQSTM1 Modulates Bone Erosions in a Murine Model of Rheumatoid Arthritis
Adelheid Korb-Pap¹, Anja Römer-Hillmann¹, Marianne Heitzmann¹, Masaru Kato², Kerstin Klein², Caroline Ospelt², Steffen Gay³, Susanne Buergis⁴, Thomas Pap¹, Thomas Weide⁵, André Gessner⁴ and Hermann Pavenstädt⁵, ¹Institute of Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ²Center of Experimental Rheumatology, University Hospital Zürich, Zurich, Switzerland, ³Center of Experimental Rheumatology, University Hospital Zürich, Zürich, Switzerland, ⁴Department of Immunology, University Erlangen, Erlangen, Germany, ⁵Department of Nephrology and Rheumatology, University Hospital Muenster, Muenster, Germany
Background/Purpose: Rheumatoid arthritis (RA) is characterised by massive bone erosions leading to irreversible joint destructions. In this context, the multi-adapter protein p62/SQSTM1 is of interest…
Abstract Number: 2421 • 2017 ACR/ARHP Annual Meeting
Aberrant Expression of CaMK4 in CD4 Positive T Cells Predicts Poor Response to Treatment in Patients with Active Rheumatoid Arthritis
Tomohiro Koga¹, Tomohito Sato¹, Masataka Umeda², Shoichi Fukui², Ayako Nishino¹, Shinya Kawashiri², Naoki Iwamoto², Kunihiro Ichinose², Mami Tamai¹, Tomoki Origuchi³, Hideki Nakamura² and Atsushi Kawakami⁴, ¹Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ²Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ³Department of Rehabilitation Sciences, Nagasaki University, Nagasaki, Japan, ⁴Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease arising from a breakdown of peripheral tolerance, which leads to aberrant Th1- or Th17-driven immune…
Abstract Number: 408 • 2017 ACR/ARHP Annual Meeting
CR6086 Is Highly Effective and Improves Methotrexate Effect in a Mouse Model of Rheumatoid Arthritis
Gianfranco Caselli¹, Flora Ferrari¹, Eleonora Comi¹, Marco Perrella¹, Camilla Recordati², Adriana Grotti¹, Rosanna Cavagnoli¹, Marco Lanza¹ and Lucio C. Rovati³, ¹Rottapharm Biotech, Monza, Italy, ²Mouse & Animal Pathology Lab,, Fondazione Filarete, Milano, Italy, Milano, Italy, ³Clinical Research Department, Rottapharm Biotech, Monza, Italy
Background/Purpose: CR6086, a selective EP4 antagonist, dose-dependently improves disease features in rheumatoid arthritis (RA) models in rodents. Indeed, recent studies highlight the role of the…
Abstract Number: 1337 • 2017 ACR/ARHP Annual Meeting
ASN002, a Novel Dual SYK/JAK Inhibitor, Demonstrates Strong Efficacy in a Rat Model of Collagen-Induced Arthritis
David Zammit¹, Sanjeeva Reddy¹, Roger Smith¹, Nitin Damle² and Sandeep Gupta¹, ¹Asana BioSciences LLC, Lawrenceville, NJ, ²Preclinical R&D, Sun Pharma Advanced Research Co. Ltd, Mumbai, India
Background/Purpose: Spleen tyrosine kinase (SYK) and Janus kinase (JAK) mediate signaling in immune cells and hematopoietic cells important for the initiation and progression of rheumatoid…
Abstract Number: 2563 • 2017 ACR/ARHP Annual Meeting
SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
Akiko Nagasu¹, Tomoyuki Mukai¹, Masanori Iseki², Hajime Nagasu³, Shunichi Fujita¹, Takafumi Mito¹, Shoko Kodama¹, Yumi Sasae⁴, Naoki Kashihara³, Katsuhiko Ishihara², Yasuyoshi Ueki⁵ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ³Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Rheumatology, Kawasaki Medical School, Kurashiki Okayama, Japan, ⁵Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City, Missouri-Kansas City, MO
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, leading to multiple organ dysfunction. SH3BP2 (Src homology domain 3…
Abstract Number: 503 • 2017 ACR/ARHP Annual Meeting
BMS-986195 Is a Highly Selective and Rapidly Acting Covalent Inhibitor of Bruton’s Tyrosine Kinase with Robust Efficacy at Low Doses in Preclinical Models of RA and Lupus Nephritis
JR Burke, KM Gillooly, MA Pattoli, L Cheng, S Skala, EM Heimrich, TL Taylor, C Pulicicchio, DW Kukral, T Petrone, IM Catlett, N Zheng, W Li, SH Watterson and JA Tino, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a member of the Tec family of non-receptor tyrosine kinases essential in…
Abstract Number: 1339 • 2017 ACR/ARHP Annual Meeting
Role of Hexokinase-2 in Synovial Lining Hypertrophy in Murine Arthritis
Marta Fernandez Bustmanate¹, Jeffrey Smith², Adam Paul Croft³, Gary S. Firestein⁴, Chris Buckley⁵, Shigeki Miyamoto² and Monica Guma⁶, ¹Medicine, UCSD, San Diego, CA, ²Pharmacology, UCSD, La Jolla, CA, ³Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Medicine, University of California San Diego, La Jolla, CA, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Medicine, UCSD, La Jolla, CA
Background/Purpose: Recent studies indicate that fibroblast-like synoviocyte (FLS) glucose metabolism is altered in rheumatoid arthritis (RA). Hexokinases (HKs) catalyze the first step in glucose metabolism.…
Abstract Number: 2574 • 2017 ACR/ARHP Annual Meeting
Interleukin-33 Ameliorates Murine Lupus Via Induction of Regulatory T Cells and M2 Macrophage Polarisation
Mo Yin Mok¹, Ka Sin Law², Wing Yin Kong¹, Ge Liu¹, Wallace Lau², C Luo², FP Huang³, GC Chan⁴ and Kwok Wah Chan³, ¹Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, Hong Kong, ²Department of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ³Department of Pathology, University of Hong Kong, Hong Kong, Hong Kong, ⁴Department of Paediatrics, University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: The levels of IL-33, a Th2 promoting cytokine, and the soluble form of its receptor ST2 were reported to be elevated in serum of…
Abstract Number: 48 • 2017 ACR/ARHP Annual Meeting
Modulation of Subchondral Bone Turnover Is Associated with Alteration of Cartilage Tissue Quality
Cedric Lavet, Isabelle Badoud and Patrick Ammann, Division of Bone Diseases, Geneva, Switzerland
Background/Purpose: Osteochondral unit is a bio composite responsible for an optimal distribution of load during movements and axial compression of a joint. Any alteration of…
Abstract Number: 863 • 2017 ACR/ARHP Annual Meeting
Functionally Distinct Pathogenic Subsets of Fibroblasts Exist within the Inflamed Synovial Membrane and Mediate Specific Aspects of Inflammatory Disease Pathology
Adam Paul Croft¹, Joana Campos², Loriane Savary², Emma Bishop², Jason Turner¹, Guillaume Desanti², Francesca Barone³, Andrew Filer³ and Chris Buckley², ¹Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Fibroblasts are key effector cells in the persistence of synovial inflammation and joint damage. It is not yet known whether specific subsets of synovial…
Abstract Number: 1578 • 2017 ACR/ARHP Annual Meeting
The Initiation, but Not the Persistence, of Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats Is Crucially Dependent on the IL-23 Axis
Melissa van Tok^1,2, Songqing Na³, Joel Taurog⁴, Dominique Baeten^2,5 and Leonie van Duivenvoorde^1,2, ¹Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology/Experimental immunology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ³Eli Lilly and Company, Indianapolis, IN, ⁴Dept Int Med-Rheum Dis Div, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Clinical Immunology and Rheumatology, Amsterdam Rheumatology and immunology Center, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: IL-17A is a central driver of spondyloarthritis (SpA) pathology. IL-17A production was originally proposed to be IL-23 dependent. Emerging preclinical and clinical evidence from…
Abstract Number: 2927 • 2017 ACR/ARHP Annual Meeting
Interferon Regulatory Factor (IRF) 7 in Type I IFN Signaling Represents As a Key Upstream Regulator in Early Diffuse SSc Patients and Plays Critical Role in Pathogenesis of Fibrosis
Minghua Wu¹, Gloria Salazar¹, Jun Ying¹, Julio Charles², Xiaodong Zhou³, Maureen D. Mayes² and Shervin Assassi², ¹Department of Internal Medicine - Rheumatology, University of Texas McGovern Medical School, Houston, TX, ²University of Texas McGovern Medical School, Houston, TX, ³Internal Medicine-Rheumatology, University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Previous global gene expression studies of SSc patients revealed presence of a prominent type I interferon (IFN) signature. IRF7 is a key transcription factor…
Abstract Number: 57 • 2017 ACR/ARHP Annual Meeting
Accelerated Development of Aging-Associated and Instability-Induced Osteoarthritis in 12/15-Lipoxygenase Deficient Mice
Lauris Habouri¹, Yassine Ouhaddi¹, Gadid Guedi¹, Jean-Pierre Pelletier², Johanne Martel-Pelletier², mohamed benderdour¹ and Hassan Fahmi², ¹Medicine, CRCHUM, Montreal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada
Background/Purpose: 12/15-Lipoxygenase (12/15-LOX) catalyzes the generation of various anti-inflammatory lipid mediators, and has been implicated in several inflammatory and degenerative diseases. However, there is currently…

« Previous Page
1
…
4
5
6
7
8
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].